We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
+11.94%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$403M
AUM Growth
+$128M
(+46%)
Cap. Flow
+$111M
Cap. Flow
% of AUM
27.45%
Top 10 Holdings %
Top 10 Hldgs %
71.78%
Holding
84
New
19
Increased
11
Reduced
3
Closed
50
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$26.4M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$24.8M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$24.1M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
+$18.2M |
| 5 |
NUAN
Nuance Communications, Inc.
NUAN
|
+$15.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$20.7M |
| 2 |
Viatris
VTRS
|
+$19.6M |
| 3 |
Labcorp
LH
|
+$11M |
| 4 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$10.3M |
| 5 |
Zai Lab
ZLAB
|
+$8.42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 71.82% |
| 2 | Technology | 3.61% |
| 3 | Industrials | 0.52% |
| 4 | Communication Services | 0% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Curis
CRIS
$8.86M
| – | – |
-902
| Closed | -$2.95M |
|
52
Elevance Health
ELV
$84.8B
| – | – |
-23,374
| Closed | -$7.5M |
|
53
Flowers Foods
FLO
$1.57B
| – | – |
-10,182
| Closed | -$230K |
|
54
General Mills
GIS
$19.2B
| – | – |
-4,799
| Closed | -$282K |
|
55
Hormel Foods
HRL
$13.9B
| – | – |
-6,148
| Closed | -$287K |
|
56
Hershey
HSY
$36.1B
| – | – |
-1,842
| Closed | -$281K |
|
57
Incyte
INCY
$24.3B
| – | – |
-67,384
| Closed | -$5.86M |
|
|
K
58
DELISTED
Kellanova
K
| – | – |
-4,703
| Closed | -$275K |
|
59
Kimberly-Clark
KMB
$37.4B
| – | – |
-2,291
| Closed | -$309K |
|
|
60
Labcorp
LH
$25.4B
| – | – |
-62,978
| Closed | -$11M |
|
61
Mondelez International
MDLZ
$79.9B
| – | – |
-6,608
| Closed | -$386K |
|
62
McCormick & Company Non-Voting
MKC
$14.1B
| – | – |
-2,863
| Closed | -$274K |
|
|
MREO
63
Mereo BioPharma
MREO
$48.4M
| – | – |
-728,710
| Closed | -$2.61M |
|
64
Merck
MRK
$317B
| – | – |
-3,805
| Closed | -$297K |
|
|
MRSN
65
DELISTED
Mersana Therapeutics
MRSN
| – | – |
-10,879
| Closed | -$7.24M |
|
66
Neurocrine Biosciences
NBIX
$16.4B
| – | – |
-7,178
| Closed | -$688K |
|
67
Intellia Therapeutics
NTLA
$1.53B
| – | – |
-56,402
| Closed | -$3.07M |
|
68
Penumbra
PEN
$12.7B
| – | – |
-1,695
| Closed | -$297K |
|
69
Procter & Gamble
PG
$341B
| – | – |
-3,210
| Closed | -$447K |
|
70
Rigel Pharmaceuticals
RIGL
$756M
| – | – |
-1,456
| Closed | -$51K |
|
71
Protara Therapeutics
TARA
$225M
| – | – |
-39,225
| Closed | -$950K |
|
72
Theravance Biopharma
TBPH
$876M
| – | – |
-49,373
| Closed | -$877K |
|
73
Telus
TU
$15.4B
| – | – |
-11,793
| Closed | -$234K |
|
74
Unilever
UL
$139B
| – | – |
-3,311
| Closed | -$225K |
|
|
75
Viatris
VTRS
$20.6B
| – | – |
-1,046,794
| Closed | -$19.6M |
|
Similar funds
DCM
AMPWP
DCM
IWP
PCS
ACGDR
GEA
ECM
Tri Locum Partners's Q1 2021 Portfolio in Review
As of Q1 2021, Tri Locum Partners held 84 positions worth $403M, up 46% from $275M the previous quarter. Its ten largest holdings account for 72% of the portfolio.
Tri Locum Partners deployed $111M of net new capital in Q1 2021, opening 19 new positions and adding to 11 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 293,426 shares worth $27M.
By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 93% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Walgreens Boots Alliance, an estimated $2.05M trimmed.
- Tri Locum Partners's largest Q1 2021 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 293,426 shares worth $27M.
- Tri Locum Partners added most to Regeneron Pharmaceuticals in Q1 2021, an estimated $26.4M increase.
- Tri Locum Partners's biggest Q1 2021 reduction was Walgreens Boots Alliance, cutting an estimated $2.05M.
- Tri Locum Partners fully exited AbbVie in Q1 2021, selling an estimated $20.7M.
- Tri Locum Partners's ten largest holdings make up 72% of its $403M portfolio in Q1 2021.
- Tri Locum Partners opened 19 new positions and closed 50 in Q1 2021.
- Tri Locum Partners's portfolio value rose 46% quarter-over-quarter to $403M.
Based on Tri Locum Partners's 13F filing for Q1 2021, filed 17 May 2021.